BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104 [PMID: 35949827 DOI: 10.12998/wjcc.v10.i18.6091]
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6091.htm
Number Citing Articles
1
Ahmed Salman, Mohamed A Salman, Ahmed Elewa, Asmaa M Awwad. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-AnalysisCureus 2024;  doi: 10.7759/cureus.61547
2
Nariman Hossein-Javaheri, Michael Youssef, Yaanu Jeyakumar, Vivian Huang, Parul Tandon. The Management of Inflammatory Bowel Disease during Reproductive Years: An Updated Narrative ReviewReproductive Medicine 2023; 4(3): 180 doi: 10.3390/reprodmed4030017
3
Martina Tallarico, Caterina Palleria, Livia Ruffolo, Rocco Spagnuolo, Maria Diana Naturale, Adele Emanuela De Francesco, Caterina De Sarro, Rossella Romeo, Rita Citraro, Patrizia Doldo, Ludovico Abenavoli, Luca Gallelli, Francesco Luzza, Antonio Leo, Giovambattista De Sarro. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance StudyPharmaceutics 2022; 14(11): 2449 doi: 10.3390/pharmaceutics14112449
4
Mahmoud E. Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa R. Askar, Gamal A. Omran, Marwa A. El-Mohamdy, Radwa S. Hagag. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patientsInflammopharmacology 2024;  doi: 10.1007/s10787-024-01508-w